Financings in Brief: Diametrics Medical
This article was originally published in The Gray Sheet
Executive SummaryDiametrics Medical: Blood chemistry testing system manufacturer nets $29.3 mil. in a public offering of 3 mil. shares of its common stock for $10.50 per share. The St. Paul, Minnesota-based firm filed a registration statement for the offering in July ("The Gray Sheet" July 17, p. 31). The funds are tabbed for expanding sales and marketing, boosting manufacturing facilities, research and development of new blood analysis tests for the firm's IRMA system, as well as "general corporate purposes." UBS Securities, Vector Securities International, and Dain Bosworth have 30 days to exercise their 450,000 share over-allotment option, Diametrics says...
You may also be interested in...
The biopharma sector is often accused of a being a slow-moving engine, but a look back over the last 20 years reveals that a lot has changed. In Vivo explores the history of high-impact M&A transactions in the industry between 1999 and 2019.
The Belgian authorities are taking steps to reduce the consumption of benzodiazepine-containing medicines, and have also reiterated the risks associated with the increasing use of opioid medications.
Following closely on the heels of a medical device tax repeal win, AdvaMed CEO Scott Whitaker sat down to discuss how the industry advocacy group ended the Obamacare excise tax and what it has in store for 2020.